XML 76 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended 12 Months Ended
Apr. 01, 2020
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disaggregation of Revenue [Line Items]                          
Revenues   $ 2,422.9 $ 2,294.0 $ 1,952.0 $ 1,828.2 $ 1,863.5 $ 1,743.7 $ 1,577.8 $ 1,372.6   $ 8,497.1 $ 6,557.6 $ 5,145.6
Sanofi Collaboration Agreement, Antibody                          
Disaggregation of Revenue [Line Items]                          
Percentage of quarterly profits require to be paid for reimbursement of development costs                     10.00%    
Contingent reimbursement obligation   $ 3,103.0                 $ 3,103.0    
Starting share of profits outside the United States, based on sales, for collaborating party                     65.00%    
Starting share of profits outside the United States, based on sales, for company                     35.00%    
Ending share of profits outside the United States, based on sales, for collaborating party                     55.00%    
Ending share of profits outside the United States, based on sales, for company                     45.00%    
Share of losses outside the United States, for collaborating party                     55.00%    
Share of losses outside the United States, for company                     45.00%    
Levels of twelve month sales at which sales milestone payments would be received                   $ 1,000.0 $ 1,500.0    
Period for achieving sales target for milestone payment, rolling basis                   12 months 12 months    
Remaining amount of sales milestone payments if total sales achieve specific levels                     $ 200.0    
Sanofi Collaboration Agreement, Antibody | Minimum                          
Disaggregation of Revenue [Line Items]                          
Percentage of trial costs required to be funded by collaborating party                     80.00%    
Percentage of repayment of development balance out of profits                     30.00%    
Sanofi Collaboration Agreement, Antibody | Maximum                          
Disaggregation of Revenue [Line Items]                          
Percentage of trial costs required to be funded by collaborating party                     100.00%    
Percentage of repayment of development balance out of profits                     50.00%    
Sanofi Collaboration Agreement, Antibody | Sales-based milestone earned                          
Disaggregation of Revenue [Line Items]                          
Revenues                     $ 50.0 $ 0.0 $ 0.0
Sanofi Collaboration Agreement, Antibody | Sales-based milestone earned | First Milestone                          
Disaggregation of Revenue [Line Items]                          
Revenues     $ 50.0                    
Sanofi Collaboration Agreement, Antibody | Sales-based milestone earned | Second Milestone                          
Disaggregation of Revenue [Line Items]                          
Sales milestone payment if total sales achieve specific levels                     $ 50.0    
Praluent Agreement                          
Disaggregation of Revenue [Line Items]                          
Royalty percentage to be received on net product sales outside of the United States 5.00%                        
Percentage of damages company is responsible for 50.00%                        
Praluent Agreement | Sanofi                          
Disaggregation of Revenue [Line Items]                          
Percentage of royalty payment that can be used to offset litigation proceedings 50.00%